Clinical trials: Pancreatic Cancer Stage
Pancreatic Cancer, Neoplasm Metastasis
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.
- Conditions
- Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
- Trial name
- NCT00116389
- Testing
- talabostat mesylate tablets, gemcitabine
- Where
- 28 sites in United States
- Volunteers
- 60 people
- Sponsor
- Point Therapeutics
Pancreatic Neoplasms, Metastases, Neoplasm
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas.
- Trial name
- NCT00035035
- Testing
- GEMZAR, ALIMTA
- Where
- 114 sites in United States, Argentina and 16 more
- Sponsor
- Eli Lilly and Company
Pancreatic Neoplasms
Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
This is a single arm, single cencer, phase II clinical trial. This study aims to evaluate the efficacy and safety of Cadonilimab combined with S-1 or capecitabine as a second-line treatment for advanced pancreatic cancer.
- Trial name
- NCT06532617
- Testing
- Cadonilimab+S-1or Capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Ductal Adenocarcinoma (mPDAC)
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose…
- Trial name
- SWITCH (NCT06790602)
- Testing
- Cemiplimab Plus Gemcitabine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Diego
Metastatic Pancreatic Cancer
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and gemcitabine in combination with an investigational agent called necuparanib (M402).
- Trial name
- NCT01621243
- Testing
- nab-paclitaxel, gemcitabine, Necuparanib
- Where
- 37 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Resectable Pancreatic Cancer
GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma
To date, there have been no Canadian led neoadjuvant or peri-operative trials, this multicentre design gives the opportunity to build more experience with this strategy across Canada in more institutions.
- Trial name
- NeoPancOne (NCT04472910)
- Testing
- Modified Folforinox (mFFX)
- Where
- 8 sites in Canada
- Volunteers
- 84 people
- Sponsor
- University Health Network, Toronto
Advanced Pancreatic Cancer
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
This is a Phase Ib/II study to evaluate the safety, tolerability and efficacy of IBI343 in combination with chemotherapy in patients with advanced pancreatic cancer, including a Phase Ib safety introduction and Phase II expansion…
- Trial name
- NCT07692750
- Testing
- IBI343+ capecitabine, IBI343+Capecitabine+oxaliplatin
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Zhejiang Cancer Hospital
Carcinoma, Islet Cell, Carcinoma, Pancreas
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
This study randomized patients with advanced pancreatic islet cell tumors to receive either sunitinib or placebo. Patients who were randomized to sunitinib received 37.5 mg of sunitinib daily, those randomized to placebo received…
- Trial name
- NCT00428597
- Testing
- sunitinib malate
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 171 people
- Sponsor
- Pfizer
Pancreatic Neoplasm
Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
The purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in participants with pancreatic cancer.
- Trial name
- NCT00267020
- Testing
- enzastaurin, gemcitabine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Solid Tumors, Pancreatic Cancer
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
This is a study of ruxolitinib in combination with gemcitabine with or without nab-paclitaxel administered to patients with advanced or metastatic pancreatic cancer. The study will be conducted in two parts.
- Trial name
- NCT01822756
- Testing
- ruxolitinib, gemcitabine, nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Incyte Corporation
Locally Advanced or Metastatic Pancreatic Cancer
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Objectives Primary: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib
- Trial name
- NCT01181245
- Testing
- FG-3019
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Kyntra Bio
Unresectable Pancreatic Cancer, Nonmetastatic Pancreatic Cancer
Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.
Title: Phase II study of hypofractionated radio-chemotherapy with gemcitabine plus oxaliplatin for unresectable nonmetastatic locally advanced pancreatic cancer.
- Conditions
- Unresectable Pancreatic Cancer, Nonmetastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer
- Trial name
- NCT02035072
- Testing
- Gemcitabine, Oxaliplatin, Hypofractionated RT
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Neuroendocrine Tumors
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
The purpose of this study is to test how safe and effective the combination of RAD001 and erlotinib is in patients with neuroendocrine tumors.
- Trial name
- NCT00843531
- Testing
- RAD001, erlotinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Bladder Cancer, Pancreas Cancer
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
This multicenter, non-randomized, Phase II study will assess the efficacy, safety, and pharmacokinetics of trastuzumab emtansine in participants with HER2 overexpressing locally advanced (unresectable and not treatable with…
- Conditions
- Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma
- Trial name
- KAMELEON (NCT02999672)
- Testing
- Trastuzumab Emtansine
- Where
- 16 sites in Italy, Netherlands and 2 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Neoplasms, Digestive System Neoplasms
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared…
- Conditions
- Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- apact (NCT01964430)
- Testing
- nab-Paclitaxel, Gemcitabine
- Where
- 341 sites in United States, Australia and 19 more
- Volunteers
- 866 people
- Sponsor
- Celgene
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer.
- Conditions
- Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms
- Trial name
- NCT04406831
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nuvance Health
Advanced Pancreatic Cancer
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
To compare, in patients with advanced pancreatic cancer, the effects of IMM-101 in combination with gemcitabine to gemcitabine alone on safety and tolerability (including QoL), clinical signs and symptoms of disease, selected…
- Trial name
- NCT01303172
- Testing
- IMM-101, Gemcitabine
- Where
- 21 sites in Cyprus, Ireland and 3 more
- Volunteers
- 110 people
- Sponsor
- Immodulon Therapeutics Ltd
Pancreatic Cancer
Study of Sirolimus in Patients With Advanced Pancreatic Cancer
Pancreatic cancer is a highly malignant tumor of the digestive system.In China, the annual mortality/morbidity of pancreatic cancer is as high as 0.88:1, and the morbidity and mortality are still on the rise.
- Trial name
- NCT03662412
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.
- Trial name
- ORCHID-1 (NCT05716295)
- Testing
- MDK-703, Checkpoint Inhibitor, Immune
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Medikine, Inc.
Pancreatic Neuroendocrine Tumor
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced…
- Trial name
- NCT03204019
- Testing
- Tegafur and Temozolomide, Tegafur and Temozolomide combined with Thalidomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.